172 related articles for article (PubMed ID: 36939069)
1. Toward a statistical validation of brain signatures as robust measures of behavioral substrates.
Fletcher E; Farias S; DeCarli C; Gavett B; Widaman K; De Leon F; Mungas D
Hum Brain Mapp; 2023 Jun; 44(8):3094-3111. PubMed ID: 36939069
[TBL] [Abstract][Full Text] [Related]
2. A robust brain signature region approach for episodic memory performance in older adults.
Fletcher E; Gavett B; Crane P; Soldan A; Hohman T; Farias S; Widaman K; Groot C; Renteria MA; Zahodne L; DeCarli C; Mungas D;
Brain; 2021 May; 144(4):1089-1102. PubMed ID: 33895818
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.
Vargas R; Abbott L; Bower D; Frahm N; Shaffer M; Yu WH
PLoS Comput Biol; 2023 Jul; 19(7):e1010770. PubMed ID: 37471455
[TBL] [Abstract][Full Text] [Related]
5. Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
Penn-Nicholson A; Hraha T; Thompson EG; Sterling D; Mbandi SK; Wall KM; Fisher M; Suliman S; Shankar S; Hanekom WA; Janjic N; Hatherill M; Kaufmann SHE; Sutherland J; Walzl G; De Groote MA; Ochsner U; Zak DE; Scriba TJ;
PLoS Med; 2019 Apr; 16(4):e1002781. PubMed ID: 30990820
[TBL] [Abstract][Full Text] [Related]
6. Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM
Brunekreef B; Strak M; Chen J; Andersen ZJ; Atkinson R; Bauwelinck M; Bellander T; Boutron MC; Brandt J; Carey I; Cesaroni G; Forastiere F; Fecht D; Gulliver J; Hertel O; Hoffmann B; de Hoogh K; Houthuijs D; Hvidtfeldt U; Janssen N; Jorgensen J; Katsouyanni K; Ketzel M; Klompmaker J; Hjertager Krog N; Liu S; Ljungman P; Mehta A; Nagel G; Oftedal B; Pershagen G; Peters A; Raaschou-Nielsen O; Renzi M; Rodopoulou S; Samoli E; Schwarze P; Sigsgaard T; Stafoggia M; Vienneau D; Weinmayr G; Wolf K; Hoek G
Res Rep Health Eff Inst; 2021 Sep; 2021(208):1-127. PubMed ID: 36106702
[TBL] [Abstract][Full Text] [Related]
7. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures.
Starmans MH; Fung G; Steck H; Wouters BG; Lambin P
PLoS One; 2011; 6(12):e28320. PubMed ID: 22163293
[TBL] [Abstract][Full Text] [Related]
8. 12-year prediction of mild cognitive impairment aided by Alzheimer's brain signatures at mean age 56.
Williams ME; Elman JA; McEvoy LK; Andreassen OA; Dale AM; Eglit GML; Eyler LT; Fennema-Notestine C; Franz CE; Gillespie NA; Hagler DJ; Hatton SN; Hauger RL; Jak AJ; Logue MW; Lyons MJ; McKenzie RE; Neale MC; Panizzon MS; Puckett OK; Reynolds CA; Sanderson-Cimino M; Toomey R; Tu XM; Whitsel N; Xian H; Kremen WS
Brain Commun; 2021; 3(3):fcab167. PubMed ID: 34396116
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
10. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
[TBL] [Abstract][Full Text] [Related]
11. Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.
Lee S; Rahnenführer J; Lang M; De Preter K; Mestdagh P; Koster J; Versteeg R; Stallings RL; Varesio L; Asgharzadeh S; Schulte JH; Fielitz K; Schwermer M; Morik K; Schramm A
PLoS One; 2014; 9(10):e108818. PubMed ID: 25295525
[TBL] [Abstract][Full Text] [Related]
12. Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.
Ahdesmäki M; Lancashire L; Proutski V; Wilson C; Davison TS; Harkin DP; Kennedy RD
Stat Appl Genet Mol Biol; 2013 Oct; 12(5):619-35. PubMed ID: 24077567
[TBL] [Abstract][Full Text] [Related]
13. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data.
Shen R; Ghosh D; Chinnaiyan AM
BMC Genomics; 2004 Dec; 5(1):94. PubMed ID: 15598354
[TBL] [Abstract][Full Text] [Related]
14. Proteomic signatures predict preeclampsia in individual cohorts but not across cohorts - implications for clinical biomarker studies.
Ghaemi MS; Tarca AL; Romero R; Stanley N; Fallahzadeh R; Tanada A; Culos A; Ando K; Han X; Blumenfeld YJ; Druzin ML; El-Sayed YY; Gibbs RS; Winn VD; Contrepois K; Ling XB; Wong RJ; Shaw GM; Stevenson DK; Gaudilliere B; Aghaeepour N; Angst MS
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5621-5628. PubMed ID: 33653202
[TBL] [Abstract][Full Text] [Related]
15. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature.
Tschodu D; Ulm B; Bendrat K; Lippoldt J; Gottheil P; Käs JA; Niendorf A
PLoS One; 2022; 17(2):e0261035. PubMed ID: 35143511
[TBL] [Abstract][Full Text] [Related]
17. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma.
Yang J; Zhang A; Luo H; Ma C
Sci Rep; 2022 Jan; 12(1):1279. PubMed ID: 35075228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
